远大医药:全球创新RDC药物GPN02006研发迎来新突破

每日经济新闻
21 Apr

每经AI快讯,远大医药公告称,集团合作开发的用于诊断肝细胞癌(HCC)的全球创新放射性核素偶联药物(RDC) GPN02006,在中国开展的研究者发起的临床研究(IIT临床研究),近日取得了里程碑式突破,并于成都2025未来XDC新药大会中公开发表了临床结果。此次研究进展,标志着集团在抗肿瘤核药研发领域再次取得重大突破,GPN02006有望成为全球首个针对GPC-3靶点的HCC诊断类RDC产品。(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10